Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Chemo-Immunotherapy Versus Immunotherapy Alone in Carcinoma in Situ of the Urinary Bladder
NCT00023842Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2001
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of mitomycin c in bladder cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Complete Response Rate. Started Jun 2001; status: completed.
02
Drugs
mitomycin c
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00023842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023842.